Earnings Call · Q3 FY2021·2021-11-11

Q3 21EPS +21.74%·Rev n/aQ2 21EPS +22.73%·Rev n/aQ1 21EPS +13.64%·Rev n/aQ4 20EPS -35.29%·Rev n/a⚠ consensus missing

DiaMedica Therapeutics Inc. DMAC

Rick Pauls — Chief Executive Officer

Scott Kellen — Chief Financial Officer

+1.6%1d on move date+1.5% vs SPY3d−9.6%5d−13.9%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DMAC calls or request research access.

More DMAC calls Browse calls Request research access